Fertility preservation options in breast cancer patients

References

• Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 2011;47:74–83
   PubMed Web of Science ®Google Scholar
• Valachis A, Tsali L, Pesce LL, et al. Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv 2010;65:786–93
   PubMed Web of Science ®Google Scholar
• Merlo DF, Ceppi M, Filiberti R, et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. Breast Cancer Res Treat 2012;134:363–70
   PubMed Web of Science ®Google Scholar
• Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 2013;27:309–12
   Google Scholar
• Gorman JR, Usita PM, Madlensky L, Pierce JP. Young breast cancer survivors: their perspectives on treatment decisions and fertility concerns. Cancer Nurs 2011;34:32–40
   PubMed Web of Science ®Google Scholar
• Lee SH, Akuete K, Fulton J, et al. An increased risk of breast disease after delayed parity. Am J Surg 2003;185:409–12
   Web of Science ®Google Scholar
• Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors’ attitudes and experiences. Cancer 1999;86:697–709
   PubMed Web of Science ®Google Scholar
• Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500–10
   PubMed Web of Science ®Google Scholar
• Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi160–70
   PubMed Web of Science ®Google Scholar
• Partridge AH, Pagani O, Abulkhair O, et al. First international consensus for young breast cancer women (BCY1). Breast 2014;23:209–20
   PubMed Web of Science ®Google Scholar
• Bozza C, Puglisi F, Lambertini M, et al. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. Endocr Relat Cancer 2014;21:R51–65
   PubMed Web of Science ®Google Scholar
• Tomasi-Cont N, Lambertini M, Hulsbosch S, et al. Strategies for fertility preservation in young early breast cancer patients. Breast 2014;23:503–10
   PubMed Web of Science ®Google Scholar
• Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014;32:1151–6
   PubMed Web of Science ®Google Scholar
• Lambertini M, Pinto AC, Del Mastro L. Fertility issues in young breast cancer patients: what women want. J Thorac Dis 2014;6:584–8
   Google Scholar
• Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril 2013;99:496–502
   PubMed Web of Science ®Google Scholar
• Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril 2013;99:1476–84
   PubMed Web of Science ®Google Scholar
• Kasum M, Beketić-Orešković L, Peddi PF, et al. Fertility after breast cancer treatment. Eur J Obstet Gynecol Reprod Biol 2014;173:13–18
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum L, Bungum M, et al. Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online 2005;11:679–84
   PubMed Web of Science ®Google Scholar
• von Wolff M, Thaler CJ, Frambach T, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 2009;92:1360–5
   PubMed Web of Science ®Google Scholar
• Kuang Y, Chen Q, Hong Q, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online 2014;29:684–91
   PubMed Web of Science ®Google Scholar
• Martínez F, Clua E, Devesa M, et al. Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes. Fertil Steril 2014;102:1307–11
   PubMed Web of Science ®Google Scholar
• Meirow D, Raanani H, Maman E, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril 2014;102:488–495.e3
   PubMed Web of Science ®Google Scholar
• Rodriguez-Walberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol 2010;53:753–62
   PubMed Web of Science ®Google Scholar
• Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril 2012;98:1363–9
   PubMed Web of Science ®Google Scholar
• Sönmezer M, Türkçüoğlu I, Coşkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 2011;95:2125.e9–11
   PubMed Web of Science ®Google Scholar
• Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010;20:783–8
   PubMed Web of Science ®Google Scholar
• Oktay K, Kim J, Bedoschi G, Tursan V. Safety of letrozole-gonadotropin controlled ovarian stimulation protocol in women with breast cancer undergoing fertility preservation before or after tumor resection via embryo or oocyte cryopreservation: a prospective cohort study. San Antonio Breast Cancer Symposium; 2014 Dec 9–11; San Antonio, Texas.1077 p. (P5-15-02)
   Google Scholar
• Azim AA, Constantini-Ferrando M, Lostrito K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metabol 2007;92:2197–200
   PubMed Web of Science ®Google Scholar
• Kim SS, Klemp J, Fabian C. Breast cancer and fertility preservation. Fertil Steril 2011;95:1535–43
   PubMed Web of Science ®Google Scholar
• Lawrenz B, Jauckus J, Kupka M, et al. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril 2010;94:2871–3
   PubMed Web of Science ®Google Scholar
• Fasano G, Fontenelle N, Vannin AS, et al. A randomized controlled trial comparing two vitrification methods versus slow-freezing for cryopreservation of human cleavage stage embryos. J Assist Reprod Genet 2014;31:241–7
   PubMed Web of Science ®Google Scholar
• Levron J, Leibovitz O, Brengauz M, et al. Cryopreservation of day 2–3 embryos by vitrification yields better outcome than slow freezing. Gynecol Endocrinol 2014;30:202–4
   PubMed Web of Science ®Google Scholar
• Barcroft J, Dayoub N, Thong KJ. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation. Assist Reprod Genet 2013;30:1407–13
   PubMed Web of Science ®Google Scholar
• Martinez F, Devesa M, Coroleu B, et al. Cancer and fertility preservation: Barcelona consensus meeting. Gynecol Endocrinol 2013;29:285–91
   PubMed Web of Science ®Google Scholar
• Konc J, Kanyó K, Kriston R, et al. Cryopreservation of embryos and oocytes in human assisted reproduction. Biomed Res Int 2014;2014:307268
   Web of Science ®Google Scholar
• Martinez-Burgos M, Herrero L, Megias D, et al. Vitrification versus slow freezing of oocytes: effects on morphologic appearance, meiotic spindle configuration, and DNA damage. Fertil Steril 2011;95:374–7
   PubMed Web of Science ®Google Scholar
• Smith GD, Serafini PC, Fioravanti J, et al. Prospective randomized comparison of human oocyte cryopreservation with slow-rate freezing or vitrification. Fertil Steril 2010;94:2088–95
   PubMed Web of Science ®Google Scholar
• Cil AP, Bang H, Oktay K. Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis. Fertil Steril 2013;100:492–9.e3
   PubMed Web of Science ®Google Scholar
• Rodriguez-Wallberg KA, Oktay K. Recent advances in oocyte and ovarian tissue cryopreservation and transplantation. Best Pract Res Clin Obstet Gynaecol 2012;26:391–405
   PubMed Web of Science ®Google Scholar
• Practice Committee of American Society for Reproductive Medicine. Practice Committee of Society for Assisted Reproductive Technology. Mature Oocyte Cryopreservation: a guideline. Fertil Steril 2013;99:37–43
   PubMed Web of Science ®Google Scholar
• Combelles CM, Chateau G. The use of immature oocytes in the fertility preservation of cancer patients: current promises and challenges. Int J Dev Biol 2012;56:919–29
   PubMed Web of Science ®Google Scholar
• Chian RC, Huang JY, Gilbert L, et al. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertil Steril 2009;91:2391–8
   PubMed Web of Science ®Google Scholar
• Grynberg M, El Hachem H, de Bantel A, et al. In vitro maturation of oocytes: uncommon indications. Fertil Steril 2013;99:1182–8
   PubMed Web of Science ®Google Scholar
• Lee JA, Sekhon L, Grunfeld L, Copperman AB. In-vitro maturation of germinal vesicle and metaphase I eggs prior to cryopreservation optimizes reproductive potential in patients undergoing fertility preservation. Curr Opin Obstet Gynecol 2014;26:168–73
   PubMed Web of Science ®Google Scholar
• Chian RC, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril 2013;99:1173–81
   PubMed Web of Science ®Google Scholar
• ISFP Practice Committee, Kim SS, Donnez J, Barri P, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet 2012;29:465–8
   PubMed Web of Science ®Google Scholar
• Mathias FJ, D'Souza F, Uppangala S, et al. Ovarian tissue vitrification is more efficient than slow freezing in protecting oocyte and granulosa cell DNA integrity. Syst Biol Reprod Med 2014;60:317–22
   PubMed Web of Science ®Google Scholar
• von Wolff M, Dian D. Fertility preservation in women with malignant tumors and gonadotoxic treatments. Dtsch Arztebl Int 2012;109:220–6
   PubMed Web of Science ®Google Scholar
• Macklon KT, Jensen AK, Loft A, et al. Treatment history and outcome of 24 deliveries worldwide after autotransplantation of cryopreserved ovarian tissue, including two new Danish deliveries years after autotransplantation. J Assist Reprod Genet 2014;31:1557–64
   PubMed Web of Science ®Google Scholar
• Liebenthron J, Dittrich R, Toth B, et al. Orthotopic ovarian transplantation – results in relation to experience of the transplantation centers, overnight tissue transportation and transplantation into the peritoneum. Hum Reprod 2015;30:i97–8
   PubMed Web of Science ®Google Scholar
• Kim SS. Revisiting the role of heterotopic ovarian transplantation: futility or fertility. Reprod Biomed Online 2014;28:41–145
   Web of Science ®Google Scholar
• Rodriguez-Wallberg KA, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation–positive breast cancer. Oncologist 2012;17:1409–17
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion. Fertil Steril 2014;101:1237–43
   PubMed Web of Science ®Google Scholar
• Vitek WS, Shayne M, Hoeger K, et al. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril 2014;102:808–15.e1
   PubMed Web of Science ®Google Scholar
• Lambertini M, Ginsburg ES, Partridge AH. Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy. Curr Opin Obstet Gynecol 2015;27:98–107
   PubMed Web of Science ®Google Scholar
• Franco JG Jr, Oliveira JB, Petersen CG, et al. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility. Med Hypotheses 2012;78:442–5
   PubMed Web of Science ®Google Scholar
• Masters GA, Krilov L, Bailey HH, et al. Clinical cancer advances 2015: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol 2015;33:786–809
   PubMed Web of Science ®Google Scholar
• Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl Med J 2015;372:923–32
   PubMed Web of Science ®Google Scholar
• Lambertini M, Boni L, Michelotti A, et al. Long-term outcome results of the phase III Promise-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients. J Clin Oncol 2014;32:abstr 105
   Google Scholar
• Telfer EE, McLaughlin M. In vitro development of ovarian follicles. Semin Reprod Med 2011;29:15–23
   PubMed Web of Science ®Google Scholar
• Kedem A, Hourvitz A, Fisch B, et al. Alginate scaffold for organ culture of cryopreserved-thawed human ovarian cortical follicles. J Assist Reprod Genet 2011;28:761–9
   PubMed Web of Science ®Google Scholar
• Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med 2013;5:185ra62
   PubMed Web of Science ®Google Scholar
• Li F, Turan V, Lierman S, et al. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Hum Reprod 2014;29:107–13
   PubMed Web of Science ®Google Scholar
• Morgan S, Lopes F, Gourley C, et al. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS One 2013;8:e70117
   PubMed Web of Science ®Google Scholar